Theravance Biopharma, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Weiss Asset Management LP and 2 others reported changes in beneficial ownership of Theravance Biopharma, Inc. common stock on September 23, 2026.
NASDAQ
Deepika Pakianathan, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Donal O'Connor, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Dean J Mitchell, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Susannah Gray, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Alsup Laurie Smaldone, a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Rick E Winningham, CHIEF EXECUTIVE OFFICER and a Director of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Aziz Sawaf, SVP & CHIEF FINANCIAL OFFICER of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Aine Miller, SVP, DEV & HEAD OF IRE OFFICE of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Brett A. Grimaud, SVP, GEN COUNSEL AND SECRETARY of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
NASDAQ
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma, Inc., sold 13,314 shares of common stock on September 15, 2026.
NASDAQ
Rick E Winningham, CHIEF EXECUTIVE OFFICER and a Director of Theravance Biopharma, Inc., reported a transaction in 20,034 shares of common stock on August 20, 2026.
NASDAQ
Aziz Sawaf, SVP & CHIEF FINANCIAL OFFICER of Theravance Biopharma, Inc., reported a transaction in 8,112 shares of common stock on August 20, 2026.
NASDAQ
Aine Miller, SVP, DEV & HEAD OF IRE OFFICE of Theravance Biopharma, Inc., reported a transaction in 6,258 shares of common stock on August 20, 2026.
NASDAQ
Brett A. Grimaud, SVP, GEN COUNSEL AND SECRETARY of Theravance Biopharma, Inc., reported a transaction in 7,952 shares of common stock on August 20, 2026.
NASDAQ
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma, Inc., reported a transaction in 5,667 shares of common stock on August 20, 2026.
NASDAQ
Eli Samaha, a Director and 10% owner of Theravance Biopharma, Inc., reported significant purchases of company stock between June 29 and July 1, 2026.
NASDAQ
Rhonda Farnum, SVP of Commercial & Medical Affairs at Theravance Biopharma, sold 13,314 ordinary shares via a 10b5-1 plan.
NASDAQ
Theravance Biopharma director Laurie Smaldone Alsup was granted 6,009 ordinary shares and 13,398 stock options as part of annual compensation.
NASDAQ
Director Susannah Gray has been granted 6,009 ordinary shares and 13,398 stock options as part of her compensation package.
NASDAQ
Director Dean J. Mitchell has been granted 6,009 ordinary shares and 13,398 stock options as part of his compensation package.
NASDAQ
Director Donal O'Connor was granted 6,009 ordinary shares and 13,398 stock options as part of his annual compensation package.
NASDAQ
Director Deepika Pakianathan was granted 6,009 ordinary shares and 13,398 stock options as part of her compensation for service on the board.
NASDAQ
Theravance Biopharma CEO Rick Winningham withheld 20,038 shares to satisfy tax obligations related to restricted stock unit vesting.
NASDAQ
CFO Aziz Sawaf disposed of 8,670 shares of Theravance Biopharma to satisfy tax obligations related to RSU vesting.
NASDAQ
Aine Miller, SVP of Development at Theravance Biopharma, reported the withholding of 6,827 shares to satisfy tax obligations related to RSU vesting.
NASDAQ
SVP and General Counsel Brett A. Grimaud disposed of 8,829 shares to satisfy tax obligations related to restricted stock unit vesting.
NASDAQ
Rhonda Farnum, SVP of Theravance Biopharma, reported the withholding of 5,678 shares to satisfy tax obligations related to RSU vesting.
NASDAQ
Rick E. Winningham, CEO of Theravance Biopharma, Inc., reported transactions involving ordinary shares, including the acquisition of 75,000 shares.